Aurobindo Pharma subsidiary, TheraNym Biologics, has entered into an additional product schedule under its existing contract manufacturing agreement with Merck Sharp & Dohme (MSD). As part of this expansion, TheraNym will construct a new, large-scale greenfield manufacturing facility, referred to as “Unit 2”. The project involves an investment of approximately USD 150 to 175 million to install 60,000 litres of mammalian cell culture bioreactor capacity to support biological drug production.
Expanding Biological Manufacturing Capabilities
TheraNym Biologics, a subsidiary of Aurobindo Pharma, is set to bolster its manufacturing footprint through a strategic expansion of its relationship with Merck Sharp & Dohme (MSD). Following an initial partnership established in May 2024, this new product schedule marks a significant milestone in the company’s efforts to strengthen its contract manufacturing operations (CMO) for biological products.
Details of the Unit 2 Project
The core of this expansion is the construction of a dedicated, greenfield facility known as “Unit 2”. This facility is specifically designed for the production of mammalian drug substances. The infrastructure will feature a total of 60,000 litres of mammalian cell culture bioreactor capacity, complemented by advanced downstream purification infrastructure necessary for high-quality drug manufacturing.
Investment and Strategic Rationale
To realize this infrastructure project, TheraNym will commit an investment ranging from USD 150 million to 175 million. This capital expenditure is aimed at scaling up production capabilities to meet the growing demand for biological manufacturing. This development underscores Aurobindo Pharma’s commitment to deepening its presence in the high-growth biologics market and fulfilling the long-term requirements of its partners at MSD.
Source: BSE
